Genomic and clinical determinants of response to Azacitidine plus venetoclax in acute myeloid leukemia: Results from the HM-SCREEN-Japan 02 study

Tomoaki Ueda, Kentaro Fukushima, Sunggi Chi, Hiroshi Haeno, Goichi Yoshimoto, Hironori Arai, Daisuke Ikeda, Motoshi Ichikawa · 2026

Read Genomic and clinical determinants of response to Azacitidine plus venetoclax in acute myeloid leukemia: Results from the HM-SCREEN-Japan 02 study by Tomoaki Ueda, Kentaro Fukushima, Sunggi Chi, Hiroshi Haeno, Goichi Yoshimoto, Hironori Arai, Daisuke Ikeda, Motoshi Ichikawa (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0357898.txt.

Description

Ueda and seven co-authors published a 2026 PLOS ONE study on treating acute myeloid leukemia, a fast-growing blood cancer. They looked at which gene traits and clinical traits predict response to two drugs used together, azacitidine and venetoclax. The data came from a Japanese study program coded HM-SCREEN-Japan 02. Knowing who is likely to respond helps doctors pick the right therapy early for each patient.

Catalog record

CREATORTomoaki Ueda, Kentaro Fukushima, Sunggi Chi, Hiroshi Haeno, Goichi Yoshimoto, Hironori Arai, Daisuke Ikeda, Motoshi Ichikawa
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE46034
LICENSECC_BY
RIGHTSCC BY
SOURCEPLOS

Source: https://doi.org/10.1371/journal.pone.0357898

Browse the full library · About the Tower of Babel